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Introduction {#bjs10995-sec-0005}
============

Sentinel lymph node biopsy (SLNB), introduced in 1991 as a staging procedure for cutaneous melanoma, evaluates the presence of lymph node involvement[1](#bjs10995-bib-0001){ref-type="ref"}. The impact of SLNB has been studied extensively and is one of the most important prognostic indicators for recurrence and survival in patients with melanoma[2](#bjs10995-bib-0002){ref-type="ref"}, [3](#bjs10995-bib-0003){ref-type="ref"}. Consequently, sentinel node (SN) status has significant implications for treatment strategy. Patients with a positive SN usually had completion lymph node dissection (CLND), but the landmark DeCOG‐SLT trial[4](#bjs10995-bib-0004){ref-type="ref"} and Multicenter Selective Lymphadenectomy Trial (MSLT) II trial[5](#bjs10995-bib-0005){ref-type="ref"} concluded there was no significant survival benefit for CLND compared with nodal observation. In future, most patients with positive SNs will be offered routine adjuvant therapy, conceivably without preceding CLND[4](#bjs10995-bib-0004){ref-type="ref"}, [5](#bjs10995-bib-0005){ref-type="ref"}, [6](#bjs10995-bib-0006){ref-type="ref"}, [7](#bjs10995-bib-0007){ref-type="ref"}, [8](#bjs10995-bib-0008){ref-type="ref"}, [9](#bjs10995-bib-0009){ref-type="ref"}. Patients with negative SNs have not been included in recent adjuvant therapy trials and are usually offered regular surveillance examinations instead.

Reported recurrence rates for patients with negative SNs vary between 6 and 29 per cent[10](#bjs10995-bib-0010){ref-type="ref"}, [11](#bjs10995-bib-0011){ref-type="ref"}. When accounting for histological subtype and ulceration, the recurrence rate may increase up to 43 per cent, which, strikingly, approximates the recurrence rate in patients with positive SNs[11](#bjs10995-bib-0011){ref-type="ref"}. Perhaps these high‐risk patients with negative SNs might benefit from adjuvant therapy as well.

The eighth edition of the AJCC staging manual categorizes melanoma with a negative SN into stages IA--IIC based on ulceration and Breslow thickness (T category)[12](#bjs10995-bib-0012){ref-type="ref"}. Several other independent factors have been identified that contribute to risk of recurrence and/or melanoma‐specific mortality (MSM)[13](#bjs10995-bib-0013){ref-type="ref"}. Considering these additional clinicopathological factors in a prediction model might provide more accurate patient‐specific estimates that could be used for treatment strategy decision‐making. The objective of the present study was to identify independent prognostic factors in a large European melanoma population with negative SNs to develop and validate a prediction model for recurrence and MSM, presented in the form of a nomogram.

Methods {#bjs10995-sec-0006}
=======

Cohort characteristics {#bjs10995-sec-0007}
----------------------

A retrospective cohort collected and described previously[14](#bjs10995-bib-0014){ref-type="ref"} was used for this study. The cohort contained 4124 patients who underwent a SLNB between 1997 and 2013 in one of four European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group centres. The study was approved and performed in accordance with local ethics committee guidelines and national legislation. For purposes of the present study, a total of 3220 patients with a negative SN were identified from this cohort. Data on sex, age, diagnosis date, date of SLNB, primary tumour characteristics (Breslow thickness, ulceration), and details on recurrence and follow‐up were collected.

Procedures and follow‐up {#bjs10995-sec-0008}
------------------------

Histopathological examination of an excision biopsy of the primary melanoma led to the diagnosis in all patients. The excision biopsy was performed with total thickness excision and a narrow circumferential margin[15](#bjs10995-bib-0015){ref-type="ref"}. Eligibility for SLNB in all centres was assessed according to international guideline criteria: Breslow thickness greater than 1·0 mm or presence of risk factors, including ulceration, Clark level IV or V according to the sixth edition of the AJCC staging manual up to 2009[16](#bjs10995-bib-0016){ref-type="ref"}, and regression or mitosis greater than 1/mm[2](#bjs10995-bib-0002){ref-type="ref"} according to the seventh edition of the AJCC staging manual from 2009[17](#bjs10995-bib-0017){ref-type="ref"}. In general, a wide local excision was performed simultaneously with the SLNB, as described elsewhere[1](#bjs10995-bib-0001){ref-type="ref"}, [14](#bjs10995-bib-0014){ref-type="ref"}. Histopathological analysis of the SN was conducted according to the EORTC Melanoma Group pathology protocol[18](#bjs10995-bib-0018){ref-type="ref"}. Follow‐up strategies in EORTC centres varied, but usually consisted of clinical examination two to four times per year for 5--10 years[15](#bjs10995-bib-0015){ref-type="ref"}, [19](#bjs10995-bib-0019){ref-type="ref"}.

Outcomes {#bjs10995-sec-0009}
--------

Outcomes of interest were recurrence and MSM, calculated from date of SLNB to date of first recurrence or death. When there was multisite first recurrence, the site with the worst prognosis was scored as the first site. Subsequently, recurrence was defined as new locoregional recurrence only: in‐transit metastasis or satellites, regional nodal recurrence in similar SN basin (with or without concurrent locoregional disease), or distant nodal or systemic recurrence (with or without concurrent regional nodal and/or locoregional disease). As the type of recurrence does not have clinical consequences at first (all patients with recurrence will undergo several diagnostic tests anyway) and to retain as much statistical power and as few methodological issues as possible, all recurrence was the outcome used for the prediction model. Median follow‐up from date of SLNB to date of last follow‐up was calculated, applying the reversed Kaplan--Meier method; deaths were censored. Disease‐free survival (DFS) was calculated from date of SLNB to date of first recurrence; lost to follow‐up or death was censored. Melanoma‐specific survival (MSS) was calculated from date of SLNB to date of MSM; lost to follow‐up or death from other causes was censored.

Statistical analysis {#bjs10995-sec-0010}
--------------------

The checklist proposed by the AJCC was used for guidance in building a high‐quality prediction model[20](#bjs10995-bib-0020){ref-type="ref"}. Associations between possible prognostic factors and recurrence were studied with Cox regression analysis. The following nine variables were identified as possible prognostic factors based on clinical experience, literature review and availability of sufficient data: sex, age, ulceration, location, histology, Breslow thickness, level of invasion (Clark level), total number of SNs removed and multiple SN fields. To make efficient use of the available data an advanced multiple imputation of missing values strategy (5 imputations) was applied[21](#bjs10995-bib-0021){ref-type="ref"}. The possible non‐linearity of the continuous variables (age, Breslow thickness and total number of SNs removed) was modelled by logarithmic transformation. Independent prognostic factors were selected with multivariable backward selection. Linear predictor values (the sum of truncated predictor values times their predictor effects) were scaled and rounded to a risk score with integer values between 0 and 100. Because recurrence and MSM are strongly related, the final recurrence prediction model based on data from all four EORTC centres was used as a basis for predicting MSM, where the baseline hazard and the slope of the recurrence prediction model were calibrated to MSM[22](#bjs10995-bib-0022){ref-type="ref"}. The advantage of this approach is that it is possible to obtain a unique risk score for each patient that translates into probabilities of both outcomes of interest: recurrence and MSM. This is in contrast to developing two independent prediction models that result in two independent risk scores with corresponding probabilities. To test the validity of this approach, the performance of an independently developed MSM prediction model was compared with that of the calibrated MSM prediction model. The absolute risk prediction of each of the two outcomes was plotted against the risk score. To reduce the overestimation of events occurring in patients with extremely high scores, the score was truncated at an integer of 15, which corresponded to the 95th percentile of score distribution in the cohort. Model performance was assessed by examining discrimination and calibration. Discrimination was measured using the concordance index (c‐index); the closer the c‐index is to 1, the better the discrimination, and a value of 0·5 indicates that the model is no better than chance[23](#bjs10995-bib-0023){ref-type="ref"}. Calibration was assessed visually by plotting the predicted probability against the actual observed frequency in quintiles of predicted recurrence and melanoma‐specific mortality. A 45° line indicates perfect calibration (when the predictive value of the model perfectly matches the patient\'s actual risk). Any deviation above or below the 45° line indicates underprediction or overprediction respectively. To evaluate the generalizability of the model across different centres, an internal--external cross‐validation was performed in which the model was fitted using data from three centres and validated in the centre that was left out[24](#bjs10995-bib-0024){ref-type="ref"}. A nomogram was developed for graphical presentation of the models. All statistical tests were two‐sided with a statistical significance level set at *P* \< 0·050. Statistic analyses were performed with IBM SPSS^®^ 22.0 (IBM, Armonk, New York, USA) and R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#bjs10995-sec-0011}
=======

From the 3220 patients identified with melanoma and negative SNs, 3180 were eligible for inclusion in the present study. Patients were excluded due to duplicates (9), urogenital melanoma (8), *in situ* melanoma (7), SLNB for recurrent disease (2), missing data (4), or discrepancy between date of recurrence and date of diagnosis and/or SLNB (10). Baseline patient and tumour characteristics for all patients and per EORTC centre are shown in *Table* [1](#bjs10995-tbl-0001){ref-type="table"}.

###### 

Baseline patient and tumour characteristics by centre

                                                                    All (*n* = 3180)      EORTC centres                                            
  ---------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ----------------------------------------------------
  Age (years)[\*](#bjs10995-note-0003){ref-type="fn"}                  55 (44--67)         51 (40--62)         63 (49--71)         51 (42--62)      55 (44--65)[†](#bjs10995-note-0004){ref-type="fn"}
  Sex                                                                                                                                              
  F                                                                    1668 (52·5)         211 (53·0)          478 (44·2)          589 (61·8)                           390 (52·2)
  M                                                                    1510 (47·5)         187 (47·0)          604 (55·8)          364 (38·2)                           355 (47·5)
  Missing                                                                2 (0·1)              0 (0)               0 (0)               0 (0)                              2 (0·3)
  Anatomical site                                                                                                                                  
  Arm                                                                  556 (17·5)           74 (18·6)          187 (17·3)          180 (18·9)                           115 (15·4)
  Leg                                                                  996 (31·3)          146 (36·7)          255 (23·6)          369 (38·7)                           226 (30·3)
  Trunk                                                                1360 (42·8)         162 (40·7)          517 (47·8)          390 (40·9)                           291 (39·0)
  Head and neck                                                         259 (8·1)           16 (4·0)           123 (11·4)           13 (1·4)                            107 (14·3)
  Missing                                                                9 (0·3)              0 (0)               0 (0)              1 (0·1)                             8 (1·1)
  Histological type                                                                                                                                
  SSM                                                                  1739 (54·7)         204 (51·3)          762 (70·4)          307 (32·2)                           466 (62·4)
  NM                                                                   885 (27·8)          134 (33·7)          204 (18·9)          353 (37·0)                           194 (26·0)
  ALM                                                                   93 (2·9)            10 (2·5)            39 (3·6)            23 (2·4)                             21 (2·8)
  LMM                                                                   139 (4·4)            5 (1·3)            42 (3·9)            75 (7·9)                             17 (2·3)
  Other                                                                 46 (1·4)             9 (2·3)             1 (0·1)             4 (0·4)                             32 (4·3)
  Missing                                                               278 (8·7)           36 (9·0)            34 (3·1)           191 (20·0)                            17 (2·3)
                                                                      (*n* = 3125)         (*n* = 392)        (*n* = 1069)         (*n* = 926)                         (*n* = 738)
  Breslow thickness (mm)[\*](#bjs10995-note-0003){ref-type="fn"}    1·70 (1·10--3·00)   1·90 (1·40--2·80)   1·30 (0·88--2·40)   2·00 (1·00--4·00)                   1·70 (1·20--2·70)
  Clark level                                                                                                                                      
  I--II                                                                 271 (8·5)           13 (3·3)            60 (5·5)           180 (18·9)                            18 (2·4)
  III                                                                  1230 (38·7)         147 (36·9)          400 (37·0)          479 (50·3)                           204 (27·3)
  IV                                                                   1354 (42·6)         188 (47·2)          569 (52·6)          219 (23·0)                           378 (50·6)
  V                                                                     140 (4·4)           18 (4·5)            31 (2·9)            41 (4·3)                             50 (6·7)
  Missing                                                               185 (5·8)           32 (8·0)            22 (2·0)            34 (3·6)                            97 (13·0)
  Ulceration                                                                                                                                       
  No                                                                   2264 (71·2)         242 (60·8)          874 (80·8)          604 (63·4)                           544 (72·8)
  Yes                                                                  788 (24·8)           92 (23·1)          182 (16·8)          339 (35·6)                           175 (23·4)
  Missing                                                               128 (4·0)           64 (16·1)           26 (2·4)            10 (1·0)                             28 (3·7)
  Mitosis                                                                                                                                          
  No                                                                    39 (1·2)            11 (2·8)              0 (0)               0 (0)                              28 (3·7)
  Yes                                                                   112 (3·5)           59 (14·8)             0 (0)               0 (0)                              53 (7·1)
  Missing                                                              3029 (95·3)         328 (82·4)          1082 (100)           953 (100)                           666 (89·2)
                                                                      (*n* = 3039)         (*n* = 397)        (*n* = 1072)         (*n* = 823)                         (*n* = 747)
  Total no. of SNs[\*](#bjs10995-note-0003){ref-type="fn"}              1 (1--2)            2 (1--2)            1 (1--2)            1 (1--1)                             2 (2--3)
  Multiple SN fields                                                                                                                               
  No                                                                   2768 (87·0)         337 (84·7)          918 (84·8)           953 (100)                           560 (75·0)
  Yes                                                                  412 (13·0)           61 (15·3)          164 (15·2)             0 (0)                             187 (25·0)

Values in parentheses are percentages unless indicated otherwise;

values are median (i.q.r.).

Based on 741 patients. EORTC, European Organization for Research and Treatment of Cancer; SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; SN, sentinel node.

Median duration of follow‐up for all survivors was 61 (i.q.r. 29--99) months. Recurrence occurred in 496 patients (15·6 per cent). The DFS rate at 5 and 10 years was 86·7(s.e. 0·7) and 72·8(1·3) per cent respectively. Some 277 patients (8·7 per cent) died from melanoma. The MSS rate at 5 and 10 years was 91·5(0·6) and 84·8(1·0) per cent respectively. Details of outcome and follow‐up for all patients and per EORTC centre are depicted in *Table* [2](#bjs10995-tbl-0002){ref-type="table"}.

###### 

Outcomes and follow‐up by centre

                                                                                          All (*n* = 3180)   EORTC centres                               
  -------------------------------------------------------------------------------------- ------------------ --------------- ------------- -------------- -------------
  Recurrence                                                                                                                                             
  Yes                                                                                        496 (15·6)        91 (22·9)      94 (8·7)      191 (20·0)    120 (16·1)
  No                                                                                        2684 (84·4)       307 (77·1)     988 (91·3)     762 (80·0)    627 (83·9)
  Recurrence type[†](#bjs10995-note-0007){ref-type="fn"}                                                                                                 
  Locoregional                                                                               142 (28·6)         34 (37)        25 (27)      38 (19·9)      45 (37·5)
  Regional nodal                                                                             122 (24·6)         14 (15)        32 (34)      48 (25·1)      28 (23·3)
  Distant                                                                                    194 (39·1)         43 (47)        37 (39)      67 (35·1)      47 (39·2)
  Unknown                                                                                     38 (7·7)           0 (0)          0 (0)       38 (19·9)        0 (0)
  Additional surgery[‡](#bjs10995-note-0008){ref-type="fn"}                                                                                              
  Yes                                                                                         13 (0·4)         13 (3·3)         0 (0)         0 (0)          0 (0)
  n.r.                                                                                      3167 (99·6)       385 (96·7)     1082 (100)     953 (100)      747 (100)
  Radiotherapy                                                                                                                                           
  Yes                                                                                         24 (0·8)         24 (6·0)         0 (0)         0 (0)          0 (0)
  n.r.                                                                                      3156 (99·2)       374 (94·0)     1082 (100)     953 (100)      747 (100)
  Chemotherapy                                                                                                                                           
  Yes                                                                                         12 (0·4)         12 (3·0)         0 (0)         0 (0)          0 (0)
  n.r.                                                                                      3168 (99·6)       386 (97·0)     1082 (100)     953 (100)      747 (100)
  Novel therapy[§](#bjs10995-note-0009){ref-type="fn"}                                                                                                   
  Yes                                                                                         22 (0·7)         16 (4·0)         0 (0)         0 (0)         6 (0·8)
  n.r.                                                                                      3158 (99·3)       382 (96·0)     1082 (100)     953 (100)     741 (99·2)
  Duration of follow‐up for survivors (months)[\*](#bjs10995-note-0006){ref-type="fn"}      61 (29--99)      94 (59--131)    33 (12--68)   87 (50--127)   57 (35--84)
  Status                                                                                                                                                 
  No evidence of disease                                                                    2736 (86·0)       318 (79·9)     984 (90·9)     786 (82·5)    648 (86·7)
  Alive with disease                                                                          90 (2·8)         12 (3·0)       23 (2·1)       20 (2·1)      35 (4·7)
  Died from disease                                                                          277 (8·7)         56 (14·1)      41 (3·8)      139 (14·6)     41 (5·5)
  Died from other cause                                                                       75 (2·4)         12 (3·0)       34 (3·1)       8 (0·8)       21 (2·8)
  n.r.                                                                                        2 (0·1)            0 (0)          0 (0)         0 (0)         2 (0·3)

Values in parentheses are percentages unless indicated otherwise;

values are median (i.q.r.).

Defined as follows: locoregional recurrence only (for example in‐transit metastasis or satellites), regional nodal recurrence similar to sentinel node basin (with or without concurrent locoregional disease) and distant recurrence (with or without concurrent locoregional and/or regional nodal disease).

Includes resection of metastases or lymph node dissection.

Includes vaccines, targeted therapy and immunotherapy. EORTC, European Organization for Research and Treatment of Cancer; n.r., not reported.

*Table* [3](#bjs10995-tbl-0003){ref-type="table"} gives the results of the multivariable Cox model for recurrence including all nine candidate variables. After backwards selection and manual exclusion of Clark level (due to limited additional effect and current clinical practice), the final model for recurrence included three independent prognostic factors: ulceration, anatomical site and Breslow thickness (*Table* [4](#bjs10995-tbl-0004){ref-type="table"}). The non‐linearity of Breslow thickness was highly significant (*P* \< 0·001) and well represented by logarithmic transformation. The c‐index for the final recurrence model was 0·74 (95 per cent c.i. 0·71 to 0·76). In cross‐validation, the c‐index for a model based on three centres and applied to the centre that was left out ranged from 0·70 to 0·77. The additional prognostic value of mitotic rate (at least 1 mitosis/mm[2](#bjs10995-bib-0002){ref-type="ref"} present in 112 of 151 observations), tested in a model with the linear predictor as an offset, was not significant (*P* = 0·678). The recurrence model was reasonably calibrated across the four centres in cross‐validation (*Fig*. *S1*, supporting information).

###### 

Multivariable Cox analysis of recurrence

                                                      Hazard ratio        *P*
  ------------------------------------------------ ------------------- ----------
  Age (i.q.r. 67 *versus* 44 years)                 1·06 (0·82, 1·36)    0·920
  Sex                                                                  
  F                                                 1·00 (reference)   
  M                                                 1·20 (0·99, 1·45)    0·065
  Breslow thickness (i.q.r. 3·0 *versus* 1·1 mm)    2·47 (1·94, 3·13)   \< 0·001
  Ulceration                                                           
  No                                                1·00 (reference)   
  Yes                                               1·84 (1·50, 2·26)   \< 0·001
  Clark level                                                            0·005
  I--II                                             1·00 (reference)   
  III                                               1·59 (0·97, 2·61)  
  IV                                                1·68 (1·02, 2·75)  
  V                                                 2·70 (1·51, 4·80)  
  Anatomical location                                                    0·001
  Arm                                               1·00 (reference)   
  Leg                                               1·38 (1·03, 1·87)  
  Trunk                                             1·54 (1·15, 2·07)  
  Head and neck                                     2·12 (1·45, 3·11)  
  Histology                                                              0·336
  SSM                                               1·00 (reference)   
  NM                                                1·18 (0·93, 1·49)  
  ALM                                               1·53 (0·94, 2·51)  
  LMM                                               1·25 (0·77, 2·03)  
  Other                                             0·89 (0·45, 1·79)  
  No. of SNs (i.q.r. 2 *versus* 1)                  1·06 (0·87, 1·29)    0·800
  Multiple SN fields                                                   
  No                                                1·00 (reference)   
  Yes                                               1·15 (0·82, 1·62)    0·411

Values in parentheses are 95 per cent confidence intervals. SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; SN, sentinel node.

###### 

Final model for recurrence

                                                      Hazard ratio        *P*
  ------------------------------------------------ ------------------- ----------
  Breslow thickness (i.q.r. 3·0 *versus* 1·1 mm)    2·22 (1·97, 2·51)   \< 0·001
  Ulceration                                                           
  No                                                1·00 (reference)   
  Yes                                               1·85 (1·52, 2·25)   \< 0·001
  Anatomical site                                                      
  Arm                                               1·00 (reference)   
  Leg                                               1·35 (1·01, 1·81)    0·044
  Trunk                                             1·55 (1·17, 2·05)    0·002
  Head and neck                                     2·39 (1·66, 3·44)   \< 0·001

Values in parentheses are 95 per cent confidence intervals.

The association between the linear predictors of recurrence and MSM was even stronger (calibration slope 1·10, 95 per cent c.i. 0·96 to 1·24). The c‐index for the calibrated MSM model was 0·76 (0·73 to 0·79). In cross‐validation, the c‐index for a calibrated model based on three centres applied to the centre that was left out ranged from 0·73 to 0·80. The calibrated model was reasonably calibrated across the four centres in cross‐validation (*Fig. S2*, supporting information). The performance of this calibrated MSM prediction model, based on the baseline hazard and the slope of the recurrence model, was similar to that of the independently developed MSM prediction model (c‐index 0·77, 0·74 to 0·80) (*Table* [5](#bjs10995-tbl-0005){ref-type="table"}).

###### 

Final model for melanoma‐specific mortality

                                                      Hazard ratio        *P*
  ------------------------------------------------ ------------------- ----------
  Breslow thickness (i.q.r. 3·0 *versus* 1·1 mm)    2·37 (2·03, 2·78)   \< 0·001
  Ulceration                                                           
  No                                                1·00 (reference)   
  Yes                                               2·11 (1·62, 2·75)   \< 0·001
  Anatomical site                                                      
  Arm                                               1·00 (reference)   
  Leg                                               0·97 (0·66, 1·44)    0·881
  Trunk                                             1·70 (1·18, 2·44)    0·004
  Head and neck                                     1·80 (1·07, 3·03)    0·028

Values in parentheses are 95 per cent confidence intervals.

A three‐item risk score was developed, assigning points to each prognostic factor based on the magnitude of association with recurrence. A nomogram to calculate the score and the risk of recurrence and MSM is presented in *Fig*. [1](#bjs10995-fig-0001){ref-type="fig"}. The scores were divided into three classes based on the score distribution (each consisting of approximately one‐third of the cohort): low risk, score 0--6; intermediate risk, score 7--9; high risk, score 10 or more (*Fig*. [1](#bjs10995-fig-0001){ref-type="fig"}). For recurrence, these risk classes correspond to the following probabilities: low risk, 1·6--8·2 per cent; intermediate risk, 11·0--18·0 per cent; high risk, 23·0 per cent or above. For MSM, these risk classes correspond to the following probabilities: low risk, 0·5--3·2 per cent; intermediate risk, 4·4--8·0 per cent; high risk, 11·0 per cent or more.

![The curves refer to predicted recurrence or melanoma‐specific mortality (MSM) at 5 years. The histogram refers to the risk score distribution in the cohort; each bar represents the proportion of patients in the cohort that was assigned that specific score. The histogram was divided in tertiles: light pink bars, first tertile (low risk); medium pink bars, second tertile (intermediate risk); dark pink bars, third tertile (high risk). The nomogram incorporates three factors: ulceration, anatomical location and Breslow thickness. To calculate an individual\'s probability of 5‐year recurrence and MSM, values for the prognostic factors must be determined first (for example: ulceration; leg; Breslow thickness 2·5 mm). Second, for each value the corresponding points can be obtained by drawing a line from each value towards the points axis (in example: 2, 1 and 7 points respectively). Third, the points must be added up to obtain the total risk score (in example: risk score of 10). Finally, the 5‐year recurrence and MSM probability can be read by moving vertically from the *x*‐axis (total risk score) to the predicted risk curves and corresponding probabilities on the left *y*‐axis (for example: 23·0 per cent for recurrence and 11·0 per cent for MSM). The percentage of patients in the entire population (3180) that also had a total risk score of 10 can be determined from the histogram, as well as the corresponding percentage of patients on the right *y*‐axis (for example: 17·5 per cent)](BJS-106-217-g001){#bjs10995-fig-0001}

Discussion {#bjs10995-sec-0012}
==========

Patients with melanoma are staged according to the AJCC staging system, based on TNM criteria[12](#bjs10995-bib-0012){ref-type="ref"}. Within these stage groupings there is still marked prognostic heterogeneity, and several clinical prognostic tools have been developed to improve predictive accuracy[25](#bjs10995-bib-0025){ref-type="ref"}. None of these tools focuses specifically on outcomes in patients with negative SNs, and most predict only survival[25](#bjs10995-bib-0025){ref-type="ref"}, [26](#bjs10995-bib-0026){ref-type="ref"}.

The present study developed and validated a nomogram to predict recurrence and MSM in patients with melanoma and negative SNs. Focusing on specifically these patients is important for several reasons. They comprise a large group with highly varying prognosis, who are generally offered regular surveillance examinations with the intent to detect early (locoregional) recurrence. Follow‐up strategies vary, but usually focus on regular clinical examination for 5--10 years[15](#bjs10995-bib-0015){ref-type="ref"}, [19](#bjs10995-bib-0019){ref-type="ref"}. Some guidelines support a one‐off follow‐up visit with instructions for subsequent self‐examination after treatment for stage IA melanoma[27](#bjs10995-bib-0027){ref-type="ref"}. The recurrence rate for stage IA disease is reported to be 5 per cent[28](#bjs10995-bib-0028){ref-type="ref"}.

Besides personalized outcome prediction, the nomogram could be used to group patients. In the present study population, approximately one‐third of patients with a negative SN had an 8·2 per cent or less predicted probability of recurrence (risk score 6 or less). Surveillance strategies could be reduced in these patients, particularly as most recurrences are self‐detected, and less frequent follow‐up seems to have no effect on recurrence and self‐detection rates, and no adverse effects[29](#bjs10995-bib-0029){ref-type="ref"}, [30](#bjs10995-bib-0030){ref-type="ref"}.

However, a 5‐year risk of relapse of 48 per cent has been reported for stage IIIA melanoma[31](#bjs10995-bib-0031){ref-type="ref"}. In the present study population, approximately one‐fifth had a 30 per cent or greater predicted recurrence probability (risk score 11 or more). Surveillance strategies could be intensified in these patients, or they could be considered for adjuvant therapy (trials). The present nomogram could aid in designing clinical trials by defining inclusion criteria, or help gain better equivalence between study arms.

In the current era of effective novel therapies in both the adjuvant and therapeutic setting it is highly relevant to focus on negative SN melanoma, as it is likely that most patients with negative SNs will not be offered adjuvant therapy before first recurrence. Mortality predictions in these patients might be partly affected in the present study, as those who developed recurrent disease after 2011 were eligible to receive effective therapy.

This study has important strengths, including its large size, widely available and easily ascertainable characteristics, multicentre composition, and outcomes that are of interest to both clinicians and patients. In multivariable analysis, ulceration, anatomical site and Breslow thickness proved to be significant independent prognostic factors, in concordance with previous reports[10](#bjs10995-bib-0010){ref-type="ref"}, [11](#bjs10995-bib-0011){ref-type="ref"}, [13](#bjs10995-bib-0013){ref-type="ref"}, [16](#bjs10995-bib-0016){ref-type="ref"}, [32](#bjs10995-bib-0032){ref-type="ref"}. Clark level is no longer part of the seventh AJCC staging edition for melanoma because it was shown not to be an independent prognostic factor when corrected for mitotic rate[17](#bjs10995-bib-0017){ref-type="ref"}. As its effect was marginal in the multivariable model for recurrence, Clark level was excluded manually. All patients were treated at multidisciplinary high‐volume European melanoma centres that applied similar international guideline criteria. This minimizes variability in the interpretation of results and, as generally a policy of centralized referral of patients with melanoma eligible for SLNB is recommended, the cohort is likely to be representative of the European melanoma population with a negative SN. Another strength of the nomogram is the model performance. Discrimination and calibration were good for both the recurrence model and the calibrated model for MSM. The performance of the calibrated model for MSM was comparable to the independently developed model for MSM, indicating the validity of the applied approach. Furthermore, the models were successful in cross‐validation and showed good agreement between prediction and actual observation. Validation of the nomogram is essential to avoid overfitting and to determine generalizability[33](#bjs10995-bib-0033){ref-type="ref"}. In the present study, the prediction models were validated using the recommended internal--external validation procedure. One centre at a time was left out to cross‐validate a model developed in the other centres; as this split was not random, it qualifies as external validation[24](#bjs10995-bib-0024){ref-type="ref"}. Previous prediction models did not focus on SN‐negative melanoma[25](#bjs10995-bib-0025){ref-type="ref"}, [26](#bjs10995-bib-0026){ref-type="ref"}. The AJCC online prognostic calculator focused on localized melanoma but included both clinical and pathological stage I--II disease (thus also patients who did not undergo SLNB) and predicted only melanoma‐specific survival[34](#bjs10995-bib-0034){ref-type="ref"}. In addition, all tools but one predict survival (disease‐specific or overall)[25](#bjs10995-bib-0025){ref-type="ref"}, [35](#bjs10995-bib-0035){ref-type="ref"}. The online Sunbelt predictor ([MelanomaCalculator.com](http://melanomacalculator.com)) included patients staged by SLNB (both positive and negative) and calculates overall survival, as well as DFS and locoregional recurrence‐free survival; however, only the methodology for predicting overall survival was published[36](#bjs10995-bib-0036){ref-type="ref"}.

This study also has several limitations. The first is the retrospective design, which has inherent biases. In addition, other prognostic factors such as regression or lymphatic invasion[37](#bjs10995-bib-0037){ref-type="ref"}, [38](#bjs10995-bib-0038){ref-type="ref"} could not be incorporated in the present models due to insufficient data. They could be incorporated in next‐generation nomograms. Another variable shown to have an independent prognostic effect is mitotic rate[17](#bjs10995-bib-0017){ref-type="ref"}, [32](#bjs10995-bib-0032){ref-type="ref"}. The prognostic effect of mitotic rate was tested by introducing it as an offset term, but it was not significant. This study did not perform competing‐risk analysis, which has been done before[26](#bjs10995-bib-0026){ref-type="ref"}. Consequently the predictions are an overestimate of the actual risk, but, owing to relatively few competing events, this overestimation is expected to be limited. Presently, there is no online version of the nomogram, but it is hoped to have this available soon.
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**Fig. S1.** Calibration plots for the recurrence model. The predicted probability is plotted on the *x*‐axis, the actual probability on the *y*‐axis. A plot along the 45° line would indicate perfect calibration in which the predicted probabilities were identical to the actual outcomes

**Fig. S2.** Calibration plots for the calibrated melanoma‐specific mortality model. The predicted probability is plotted on the *x*‐axis, the actual probability on the *y*‐axis. A plot along the 45° line would indicate perfect calibration in which the predicted probabilities were identical to the actual outcomes
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Click here for additional data file.
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